Company intelligence / Profile preview

Zihipp

Bristol, Bristol, United Kingdom

Ownership: Private
Employees: ~17
Development stage: Other

Overview

Zihipp focuses on developing peptide hormone analogues for metabolic disorders. Its pipeline includes MET-097i, a long-acting GLP-1 receptor agonist in Phase 2b, and MET-233i, an amylin analog in Phase 1. Clinical data for MET-233i demonstrated significant weight loss (8.4% at day 36) in early trials.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: Peptides
Industry: Biotech

Partnerships

Imperial College LondonEOFlowSanPlena

Beyond the preview

Go deeper on Zihipp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zihipp.

Explore the full profile